# Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

> **NCT02097342** · PHASE4 · UNKNOWN · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 30 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Insulin Sensitivity/Resistance

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Placebo
- **DRUG:** Voglibose

## Key facts

- **NCT ID:** NCT02097342
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2014-11
- **Final completion:** 2015-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097342, "Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02097342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*